Literature DB >> 12679909

Expression, purification and serological analysis of hepatocellular carcinoma associated antigen HCA587 in insect cells.

Bing Li1, Hong-Yan Wu, Xiao-Ping Qian, Yan Li, Wei-Feng Chen.   

Abstract

AIM: In order to assess hepatocellular carcinoma associated antigen HCA587 as a potential target for immunotherapy, the Bac-to-Bac expression system was used to express recombinant protein HCA587 in insect cells.
METHODS: The cDNA encoding HCA587 gene was cloned into donor vector pFasBacHtb and recombinant pFasBac Htb-587 was transformed into competent cells DH10Bac. Recombinant Bacmid-587 was transfected into Sf9 insect cells using CELLFECTIN, Recombinant HCA587 protein was produced in Sf9 insect cells after infection with recombinant baculovirus, and was purified using Ni-NTA resin. Sera from HCC patients were also screened using recombinant protein HCA587.
RESULTS: The molecular weight of the recombinant protein HCA587 expressed in insect cells was approximately 43kd. Western blot results proved the recombinant protein HCA587 had the similar antigenicity with its native counterpart. Serological analysis told that the rate of seroreactivity to HCA587 was not high in HCC patients.
CONCLUSION: The recombinant protein HCA587 was successfully expressed and purified using Bac-to-Bac expression system. It paved the way for generation of specific antibody and investigation of immunohistochemical analysis and immune responses of HCC in the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679909      PMCID: PMC4611427          DOI: 10.3748/wjg.v9.i4.678

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.

Authors:  M Oiso; M Eura; F Katsura; M Takiguchi; Y Sobao; K Masuyama; M Nakashima; K Itoh; T Ishikawa
Journal:  Int J Cancer       Date:  1999-05-05       Impact factor: 7.396

2.  Production of human papillomavirus type 16 early proteins in Bac-To-Bac Expression System (GibcoBRL).

Authors:  M Schmidt; A K Olejnik; K Stepień; A M Olejnik; W Butowska; W Grajek; J B Warchoł; A Gozdzicka-Józefiak
Journal:  Folia Histochem Cytobiol       Date:  2001       Impact factor: 1.698

Review 3.  From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens.

Authors:  J L Schultze; R H Vonderheide
Journal:  Trends Immunol       Date:  2001-09       Impact factor: 16.687

4.  Expression and purification of recombinant rat eosinophil-associated ribonucleases, homologues of human eosinophil cationic protein and eosinophil-derived neurotoxin, and their characterization.

Authors:  M Nakajima; M Hirakata; T Nittoh; K Ishihara; K Ohuchi
Journal:  Int Arch Allergy Immunol       Date:  2001-07       Impact factor: 2.749

Review 5.  Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.

Authors:  D Jäger; E Jäger; A Knuth
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

6.  Identification of cancer/testis genes by database mining and mRNA expression analysis.

Authors:  Matthew J Scanlan; Claudia M Gordon; Barbara Williamson; Sang-Yull Lee; Yao-Tseng Chen; Elisabeth Stockert; Achim Jungbluth; Gerd Ritter; Dirk Jäger; Elke Jäger; Alexander Knuth; Lloyd J Old
Journal:  Int J Cancer       Date:  2002-04-01       Impact factor: 7.396

7.  Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1.

Authors:  M E Perico; D Mezzanzanica; E Luison; P Alberti; L Panza; G Russo; S Canevari
Journal:  Cancer Immunol Immunother       Date:  2000-08       Impact factor: 6.968

8.  Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis.

Authors:  Albert J W Zendman; Annemieke A van Kraats; Anneke I den Hollander; Ulrich H Weidle; Dirk J Ruiter; Goos N P van Muijen
Journal:  Int J Cancer       Date:  2002-01-10       Impact factor: 7.396

9.  A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.

Authors:  E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

10.  The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.

Authors:  Erwin S Schultz; Jacques Chapiro; Christophe Lurquin; Stéphane Claverol; Odile Burlet-Schiltz; Guy Warnier; Vincenzo Russo; Sandra Morel; Frédéric Lévy; Thierry Boon; Benoît J Van den Eynde; Pierre van der Bruggen
Journal:  J Exp Med       Date:  2002-02-18       Impact factor: 14.307

View more
  5 in total

1.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

2.  A rapid and efficient method to express target genes in mammalian cells by baculovirus.

Authors:  Tong Cheng; Chen-Yu Xu; Ying-Bin Wang; Min Chen; Ting Wu; Jun Zhang; Ning-Shao Xia
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

3.  Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice.

Authors:  Juanjuan Chen; Lijie Zhang; Weigang Wen; Jiaqing Hao; Pumei Zeng; Xiaoping Qian; Yu Zhang; Yanhui Yin
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

4.  MicroRNA-874 Functions as a Tumor Suppressor by Targeting Cancer/Testis Antigen HCA587/MAGE-C2.

Authors:  Xiao Song; Wenjie Song; Ying Wang; Jingjing Wang; Yan Li; Xiaoping Qian; Xuewen Pang; Yu Zhang; Yanhui Yin
Journal:  J Cancer       Date:  2016-03-20       Impact factor: 4.207

5.  Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses.

Authors:  Bingke Bai; Xinya Lu; Jin Meng; Qinxue Hu; Panyong Mao; Baojing Lu; Ze Chen; Zhiming Yuan; Hanzhong Wang
Journal:  Mol Immunol       Date:  2007-10-01       Impact factor: 4.407

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.